Evidence map›Paper›PMID 39355425›Full record

ArticleFrontiers in microbiology2024

Discovery of anti-infective compounds against

Jahn Nitschke, Robin Huber, Stefania Vossio, Dimitri Moreau, Laurence Marcourt, Katia Gindro, Emerson F Queiroz, Thierry Soldati, Nabil Hanna

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in microbiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Frontiers in microbiology · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Jahn NitschkeDepartment of Biochemistry, Faculty of Science, University of Geneva, Geneva, Switzerland.
Robin HuberSchool of Pharmaceutical Sciences, University of Geneva, CMU, Geneva, Switzerland.
Stefania VossioACCESS Screening Platform, NCCR Chemical Biology, Faculty of Science, University of Geneva, Geneva, Switzerland.
Dimitri MoreauACCESS Screening Platform, NCCR Chemical Biology, Faculty of Science, University of Geneva, Geneva, Switzerland.
Laurence MarcourtSchool of Pharmaceutical Sciences, University of Geneva, CMU, Geneva, Switzerland.
Katia GindroMycology Group, Research Department Plant Protection, Agroscope, Nyon, Switzerland.
Emerson F QueirozSchool of Pharmaceutical Sciences, University of Geneva, CMU, Geneva, Switzerland.
Thierry SoldatiDepartment of Biochemistry, Faculty of Science, University of Geneva, Geneva, Switzerland.
Nabil HannaDepartment of Biochemistry, Faculty of Science, University of Geneva, Geneva, Switzerland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Methods: This study evaluated the suitability of a high-throughput infection system composed of the host amoeba Results: The study confirmed both efficacy of established antibiotics such as rifampicin and bedaquiline, with activities below defined anti-mycobacterium susceptibility breakpoints, and the lack of activity of pyrazinamide against Mm. The screening revealed the promising anti-infective activities of Discussion: The study highlights the potential of biotransformation and NP-inspired derivatization approaches for drug discovery and underscores the utility of the Dd-Mm infection system in identifying novel anti-infective compounds.

Indexed as

anti-infectivesDictyostelium discoideumMycobacterium marinumnatural productsphenotypic screeningstilbene derivatives

Identifiers

PMID39355425
PMCPMC11443511

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.